Navigation Links
Peripheral Artery Disease (PAD) Patent Granted to Dimera
Date:8/11/2009

PORTLAND, Ore., Aug. 11 /PRNewswire/ -- The U.S. Patent and Trade Office (USPTO) plans to announce patent award approval on August 11 to Dimera Incorporated for treatment of symptoms of Peripheral Arterial Disease (PAD), which is alternatively known as Peripheral Vascular Disease (PVD).

"Method and Kit for reducing the symptoms of peripheral vascular disease," (Number 7572780) covers the period August 11, 2009 through July 28, 2024. Dimera President, Prof. R. Kent Hermsmeyer, said, "We are pleased to announce perhaps the most important of the Dimera patents to date. Dimera plans to further optimize our success in demonstrating the virtues of our advanced transdermal strategy that we have extensively documented in primates to greatly extend normal function in the peripheral circulation."

Hermsmeyer explains that, "The loss of normal function of blood vessels explains deterioration of the peripheral circulation, and that decline in function with age now appears to be preventable. If women and men at the peak of cardiovascular health used our discovery to counter the avoidable fall in essential molecular function - which we have identified and mapped - then the expectation of reduced mobility and even disability with advancing age might be dispelled. Rather than addressing only the symptoms of peripheral vascular disease, Dimera has taken the demanding - but arguably more powerful - approach that demands discovery and understanding of the underlying molecular mechanism at the gene level."

The significance of this patent is one of the premiere successful translations of science - cell and molecular biology - to clinically effective medicine.

About Dimera

Founded by world-renown researchers in 1997 as a pure R&D biotech, Dimera (www.dimera.net) has evolved into a drug development firm specializing in cardiovascular and smooth muscle diseases. Dimera has leveraged its expertise in physiology and biophysics into discovery of clinical applications for the prevention and treatment of cardiovascular disease. A systems approach integrating extensive preclinical coronary catheterization and molecular research have produced incisive definition of the molecular mechanism of action for steroid-mediated gene expression control.

Dimera's new drug platform is based on the discovery that low steroid levels directly control smooth muscle gene expression and thus reactivity. Smooth muscle in the wall of blood vessels, airways, and the bladder constitutes the essential (functional final common path) control element. In many cardiovascular diseases, vascular and visceral smooth muscle cell dysfunctions are a dominant direct cause of excessive constriction and obstructed flow.


'/>"/>
SOURCE Dimera Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
4. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
5. Peripheral Vascular Device Market Insights Webinar
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
10. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
11. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
(Date:2/9/2016)... ... , ... Date and time: March 1, 2016, 5:30 p.m. ... Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The ... open house for participants to learn about a new Master of Biomedical Science ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):